A - anergy 中文 - EN166

anergy n.【醫學】1.無反應性。2.無力。adj.-ergic...

aneroid
Transplantation has been developed to an effctive strategy for treatment of end stage diseases of multiple organs since 1950 ' s . despite success of current immunosuppressive drugs , transplantation immunologists and surgeons are still seeking to achieve tolerance to allograft . there are several different mechanisms such as clonal deletion , anergy , neglect , immuno regulation . which maintain tolerance to self - antigen . some strategies , derived from these mechanisms has been proved to be encouraged in suppression of allograft rejection 二十世紀五十年代以來，器官移植的進展使同種異體器官移植成為治療多種器官終末期疾病的有效手段。盡管目前免疫抑制方案非常有效，但免疫耐受仍是移植免疫學家和外科醫生關注的課題。有多個機制使免疫系統對自身抗原保持耐受，如：克隆清除、忽略、失能、免疫調節。
T cell will be apopotosis , clone depletion and / or anergy , in turn inducing an antigen - specific tolerance . ctla4 ( cytotoxic t lymphocyte associated antigen 4 ) , a prominent negative costimulator , can competitively bind with b7 , and block b7 - cd28 pathway and t cell activation by producing inhibitory singals Ctla4 ( cytotoxictlymphocyteassociatedantigen4 )作為一種主要的共刺激負調節劑，可競爭性結合b7分子，阻斷b7 - cd28途徑、并通過產生抑制性信號使t細胞活化障礙。
On the other hand , there is substanial evidences tha dcs mediate tolerane . the gm - csf - stbolated mouse bone mwderived mhc class ii + dc progendors tha are deficient in cell surface erpression of the costbolatory molecules b7 - l and b7 - 2 can induce alloanginspecific t ceil anergy in vbo . systendc adchstraion of these donor - derived dc progendors to recipients intravenously 7 days before transplantation prolonged the median graft survival tane from 9 . 5 days to 22 days wbout additional twnosuppressions in a mouse cardinc twlanation model 1995年， lul等報道表面缺乏共刺激分子，特別是缺乏cd80 ( b7 - 1 )和cd86 ( b7 - 2 )的未成熟型dc能在體外誘導同種抗原特異性的t細胞無能，而對dc的適當處理能夠使未成熟型dc潛在的耐受原性得以放大和增強，使得dc在誘導免疫耐受中具有相當重要的作用及潛在的應用價值。